/picture alliance, Bodo Schackow
Berlin If the SARS-CoV-2 infection numbers remain at the current level for a long time, there is a risk of a continued borderline situation in the intensive care units. Uwe Janssens, President of the German Interdisciplinary Association for Intensive Care and Emergency Medicine (DIVI), emphasized this today.
In view of the increasingly scarce resources, especially in the personnel area, the point now has to be to concentrate all forces, interventions and treatments that can be deferred should be temporarily avoided.
Janssens also called for legal protection for resource redistribution through to possible triage situations. Here the current situation is unsatisfactory. It is important to transparently express the state’s trust in medical professionals and to regulate the requirements for triage situations nationwide.
According to Christian Karagiannidis, scientific director of the DIVI intensive care register, the number of COVID-19 records in hospitals can be expected to rise until at least mid-January, even if the current containment measures have led to a decrease in the number of infections.
According to Karagiannidis, model calculations on the time lag between infections and hospital treatments suggest a patient number of around 6,000. This high level could well last for three to four months. There are currently around 5,200 COVID-19 patients in intensive care in Germany.
This capacity utilization is already leading to regional overload situations, as Steffen Weber-Carstens from the DIVI intensive register emphasized. The cloverleaf concept for the redistribution of patients, however, allows an adequate response through good communication. In order to prevent further operational restrictions at the hospital locations, however, the hospital staff should be vaccinated against SARS-CoV-2 as soon as possible.
Regarding vaccinations, Gernot Marx, DIVI President-designate 2021, expressed his hope that the entire population would be ready to vaccinate. Both the data on the protective effect and the side effect profile of the Biontech / Pfizer vaccine are very positive. Until the desired herd immunity is achieved, however, it will take as long as the further protective measures must continue to be followed.
Stefan Kluge, board member of DIVI, commented on the current treatment options for inpatients with COVID-19. The recently published S2k guideline on inpatient therapy for patients with COVID-19 contains key recommendations based on the latest findings. The focus of the guideline is on ensuring adequate oxygenation, correct drug thrombosis prophylaxis and therapy with dexamethasone in severe cases. © aha / aerzteblatt.de